Tarcocimab and Tabirafusp Meet Phase 3 Endpoints

At AAO 2026, Charles C. Wykoff, MD, PhD, presented positive DAYBREAK results for both Kodiak Sciences agents. A BLA submission for tarcocimab is planned later this year.

By Jim Gallagher, senior managing editor

Early ELAAVATE Data Show Promise in DME

Arshad M. Khanani, MD, FASRS, discusses preliminary safety and efficacy findings from a phase 2 study of subretinal sura-vec gene therapy.

By Arshad M. Khanani, MD, MA, FASRS, Diana V. Do, MD

Remigromig Meets Primary Endpoint in BRUNELLO Trial

Both doses of the Wnt pathway agonist met the primary noninferiority endpoint in evaluation against ranibizumab in patients with DME, Donald J. D’Amico, MD, reported at AAO.

By Jim Gallagher, senior managing editor

FDA Accepts Vamikibart BLA for Uveitic Macular Edema

New phase 3 data presented at AAO 2026 showed sustained visual and anatomic improvements through 52 weeks in the MEERKAT and SANDCAT trials.

By Jim Gallagher, senior managing editor

K8 Shows Greater GA Growth Reduction Over Time

Liangbo Shen, MD, reported additional phase 2 findings at AAO 2026 as Inflammasome Therapeutics prepares for a phase 3 trial.

By Jim Gallagher, senior managing editor

Two-Year PRISM Data Show Reduced Treatment Burden

Veeral Sheth, MD, discusses the durability, safety, and supplemental injection requirements of intravitreal 4D-150 gene therapy for wet AMD.

By Veeral S. Sheth, MD, MBA, FACS, Diana V. Do, MD

What to Expect at AAO Retina Subspecialty Day

Subspecialty Day program co-chair Diana V. Do, MD, previews the clinical, surgical, and trial-focused programming planned for the upcoming AAO meeting in New Orleans.

By Diana V. Do, MD